Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
FOXO Technologies ( (FOXO) ) has issued an announcement.
FOXO Technologies Inc. announced the formation of a new subsidiary, FOXO Acquisition Corporation, to pursue acquisitions in healthcare services and related sectors, alongside plans to create a publicly listed non-convertible preferred stock to facilitate these acquisitions. Additionally, following the unexpected passing of Interim CFO Martin Ward on June 9, 2025, Seamus Lagan has been appointed as the Interim CFO, while the company searches for a permanent replacement.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates in the healthcare and biotechnology industries, owning subsidiaries such as Rennova Community Health, Myrtle Recovery Centers, and FOXO Labs. The company focuses on healthcare services, behavioral health, and biotechnology solutions aimed at improving human health and lifespan.
Average Trading Volume: 5,216,878
Technical Sentiment Signal: Sell
Current Market Cap: $3.22M
For a thorough assessment of FOXO stock, go to TipRanks’ Stock Analysis page.